Emerging nano-carrier strategies for brain tumor drug delivery and considerations for clinical translation

David J. Lundy; Helen Nguyễn; Patrick C.H. Hsieh

doi:10.3390/pharmaceutics13081193

Emerging nano-carrier strategies for brain tumor drug delivery and considerations for clinical translation

David J. Lundy, Helen Nguyễn, Patrick C.H. Hsieh

Research output: Contribution to journal › Review article › peer-review

32 Citations (Scopus)

Abstract

Treatment of brain tumors is challenging since the blood–brain tumor barrier prevents chemotherapy drugs from reaching the tumor site in sufficient concentrations. Nanomedicines have great potential for therapy of brain disorders but are still uncommon in clinical use despite decades of research and development. Here, we provide an update on nano-carrier strategies for improving brain drug delivery for treatment of brain tumors, focusing on liposomes, extracellular vesicles and biomimetic strategies as the most clinically feasible strategies. Finally, we describe the obstacles in translation of these technologies including pre-clinical models, analytical methods and regulatory issues.

Original language	English
Article number	1193
Journal	Pharmaceutics
Volume	13
Issue number	8
DOIs	https://doi.org/10.3390/pharmaceutics13081193
Publication status	Published - Aug 2021

Keywords

Blood–brain barrier
Brain tumor
Exosome
Glioblastoma multiforme
Liposome
Nanomedicine

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.3390/pharmaceutics13081193

Cite this

@article{5192bcb808c7433cb2c32afa3fc94d59,

title = "Emerging nano-carrier strategies for brain tumor drug delivery and considerations for clinical translation",

abstract = "Treatment of brain tumors is challenging since the blood–brain tumor barrier prevents chemotherapy drugs from reaching the tumor site in sufficient concentrations. Nanomedicines have great potential for therapy of brain disorders but are still uncommon in clinical use despite decades of research and development. Here, we provide an update on nano-carrier strategies for improving brain drug delivery for treatment of brain tumors, focusing on liposomes, extracellular vesicles and biomimetic strategies as the most clinically feasible strategies. Finally, we describe the obstacles in translation of these technologies including pre-clinical models, analytical methods and regulatory issues.",

keywords = "Blood–brain barrier, Brain tumor, Exosome, Glioblastoma multiforme, Liposome, Nanomedicine",

author = "Lundy, {David J.} and Helen Nguyễn and Hsieh, {Patrick C.H.}",

note = "Funding Information: The authors are supported by the Ministry of Science and Technology, Taiwan (109-2321-B-001-012, 109-2327-B-001-001, 109-2740-B-001-002, MOST 110-2740-B-001-003, MOST 109-2636-B-038-003), the National Health Research Institutes (EX109-10907SI), and the Academia Sinica Healthy Longevity Grand Challenge (AS-HLGC-109-05), Translational Medical Research Program (AS-KPQ-110-BioMed) and Taipei Medical University-CWRU Pilot Program (108-3805-023-400). Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = aug,

doi = "10.3390/pharmaceutics13081193",

language = "English",

volume = "13",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

TY - JOUR

T1 - Emerging nano-carrier strategies for brain tumor drug delivery and considerations for clinical translation

AU - Lundy, David J.

AU - Nguyễn, Helen

AU - Hsieh, Patrick C.H.

N1 - Funding Information: The authors are supported by the Ministry of Science and Technology, Taiwan (109-2321-B-001-012, 109-2327-B-001-001, 109-2740-B-001-002, MOST 110-2740-B-001-003, MOST 109-2636-B-038-003), the National Health Research Institutes (EX109-10907SI), and the Academia Sinica Healthy Longevity Grand Challenge (AS-HLGC-109-05), Translational Medical Research Program (AS-KPQ-110-BioMed) and Taipei Medical University-CWRU Pilot Program (108-3805-023-400). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/8

Y1 - 2021/8

N2 - Treatment of brain tumors is challenging since the blood–brain tumor barrier prevents chemotherapy drugs from reaching the tumor site in sufficient concentrations. Nanomedicines have great potential for therapy of brain disorders but are still uncommon in clinical use despite decades of research and development. Here, we provide an update on nano-carrier strategies for improving brain drug delivery for treatment of brain tumors, focusing on liposomes, extracellular vesicles and biomimetic strategies as the most clinically feasible strategies. Finally, we describe the obstacles in translation of these technologies including pre-clinical models, analytical methods and regulatory issues.

AB - Treatment of brain tumors is challenging since the blood–brain tumor barrier prevents chemotherapy drugs from reaching the tumor site in sufficient concentrations. Nanomedicines have great potential for therapy of brain disorders but are still uncommon in clinical use despite decades of research and development. Here, we provide an update on nano-carrier strategies for improving brain drug delivery for treatment of brain tumors, focusing on liposomes, extracellular vesicles and biomimetic strategies as the most clinically feasible strategies. Finally, we describe the obstacles in translation of these technologies including pre-clinical models, analytical methods and regulatory issues.

KW - Blood–brain barrier

KW - Brain tumor

KW - Exosome

KW - Glioblastoma multiforme

KW - Liposome

KW - Nanomedicine

UR - http://www.scopus.com/inward/record.url?scp=85112046829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112046829&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics13081193

DO - 10.3390/pharmaceutics13081193

M3 - Review article

AN - SCOPUS:85112046829

SN - 1999-4923

VL - 13

JO - Pharmaceutics

JF - Pharmaceutics

IS - 8

M1 - 1193

ER -

Emerging nano-carrier strategies for brain tumor drug delivery and considerations for clinical translation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this